- Intrathecal nucleic acid therapeutics, offering targeted delivery of RNA and DNA-based treatments directly into the cerebrospinal fluid, are becoming increasingly vital in the management of severe neurological disorders due to their enhanced efficacy, ability to bypass the blood-brain barrier, and promising clinical outcomes in rare genetic conditions
- The escalating demand for intrathecal nucleic acid therapeutics is primarily fuelled by the rising prevalence of neurodegenerative diseases, advancements in gene silencing and antisense oligonucleotide (ASO) technologies, and increased funding for precision medicine
- North America dominated the intrathecal nucleic acid therapeutics market with the largest revenue share of 46.7% in 2024, characterized by robust healthcare infrastructure, high R&D investment in genetic therapies, and a strong presence of leading biopharma companies
- Asia-Pacific is expected to be the fastest-growing region in the intrathecal nucleic acid therapeutics market during the forecast period with a CAGR 24.1%, driven by expanding biotech capabilities, increasing government initiatives in rare disease treatment, and rising healthcare expenditure in countries such as China, Japan, and India
- The intrathecal segment dominated the intrathecal nucleic acid therapeutics market with a market share of 43.3% in 2024, owing to its precision in delivering therapeutics directly to the central nervous system, which improves drug bioavailability and therapeutic outcomes for CNS-related disorders
